Scholarlink

Background <p>Recent progress in immunotherapy has developed novel approaches to overcome some immune evasion mechanisms in acute myeloid leukemia (AML). Notably, antibody-drug conjugates (ADCs) emerged as a promising method. This study presents real-world data on AML patients treated with Gemtuzumab ozogamicin (GO) (ADCs) to guide treatment strategies and provide further evidence regarding its efficacy.</p> Methods <p>Thirty adult AML patients (treatment-naïve and relapsed/refractory), FLT3 negative and CD33-positive, were enrolled in this study to receive GO alone or with chemotherapy. Treatment response was evaluated using European Leukemia Net guidelines.</p> Results <p>Result show a 50% overall response rate (46.7% complete remission and 3.3% partial remission). higher complete remission rates (78.5%) in treatment-naive AML patients compared to relapsed/refractory cases (21.5%). Following initial induction, 10 patients-maintained remission, while 14 succumbed to the disease, predominantly early during induction therapy. The Survival advantage in newly diagnosed patients (10.45months) compared to those with relapsed/refractory patients (5.63 months, <i>P</i> = 0.015).</p> Conclusion <p>Go served as a target therapy and served as an antibody-based target therapies, attained significant rate of response and improved survival outcomes in both treatment- naïve and those with relapsed/refractory AML patients, that emphasizes its role as part of induction and salvage regimens in parallel enhanced supportive care could further improve outcome.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-CD33 Antibody-Drug Conjugate (Gemtuzumab ozogamicin) in Adult Acute Myeloid Leukemia: Real Life Data from Iraq

  • 期刊论文

  • 发表日期：

    2025年12月5日

查看全文
  • Alaadin Suhham Naji,
  • Luma Essa Hammodi,
  • Shahla’a Fadhil Sabir,
  • Ahmed Shamil Hashim,
  • Alaa Fadhil Alwan

摘要

Background

Recent progress in immunotherapy has developed novel approaches to overcome some immune evasion mechanisms in acute myeloid leukemia (AML). Notably, antibody-drug conjugates (ADCs) emerged as a promising method. This study presents real-world data on AML patients treated with Gemtuzumab ozogamicin (GO) (ADCs) to guide treatment strategies and provide further evidence regarding its efficacy.

Methods

Thirty adult AML patients (treatment-naïve and relapsed/refractory), FLT3 negative and CD33-positive, were enrolled in this study to receive GO alone or with chemotherapy. Treatment response was evaluated using European Leukemia Net guidelines.

Results

Result show a 50% overall response rate (46.7% complete remission and 3.3% partial remission). higher complete remission rates (78.5%) in treatment-naive AML patients compared to relapsed/refractory cases (21.5%). Following initial induction, 10 patients-maintained remission, while 14 succumbed to the disease, predominantly early during induction therapy. The Survival advantage in newly diagnosed patients (10.45months) compared to those with relapsed/refractory patients (5.63 months, P = 0.015).

Conclusion

Go served as a target therapy and served as an antibody-based target therapies, attained significant rate of response and improved survival outcomes in both treatment- naïve and those with relapsed/refractory AML patients, that emphasizes its role as part of induction and salvage regimens in parallel enhanced supportive care could further improve outcome.